Catalog Pro5® MHC Class I Pentamers

 

Pentamers by Research Area

AAV HIV/SIV Minor Histocompatibility Antigen Trypanosoma
Adenovirus HPV Model Antigen Tuberculosis
Autoimmunity HSV MuLV Vaccinia
Cancer HTLV Negative Varicella Zoster Virus
Chlamydia Influenza Other VSV
CMV JC Virus RSV West Nile Virus
EBV LCMV Sendai Virus Yellow Fever Virus
HBV Listeria SV40 Virus
HCV Malaria Toxoplasma gondii

 

AAV

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*01:01 886 SADNNNSEY AAV VP1 492-500
B*07:02 651 VPQYGYLTL AAV2 372-380

 

Adenovirus

Publications citing Adenovirus Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*01:01 686 TDLGQNLLY Adenovirus 5 Hexon 886-894
A*24:02 684 TYFSLNNKF Adenovirus 5 Hexon 37-45
B*07:02 989 KPYSGTAYNAL Adenovirus Hexon 114-124
B*07:02 685 KPYSGTAYNSL AdV Hexon
B*35:01 1346 IPYLDGTFY AdV Hexon
H-2Db 2206 SGPSNTPPEI Ad5 E1A 234–243

 

Autoimmunity

Publications citing AutoImmunity Pentamers
Case studies of Customer
Research into AutoImmunity

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 151 KLQVFLIVL T1D Diabetes human prepro islet amyloid polypeptide ppIAPP 5-13
A*02:01 954 LNIDLLWSV T1D Diabetes IGRP 228–236
A*02:01 851 HLVEALYLV Insulin B chain 10-18
A*02:01 393 VMNILLQYV GAD65 114-123
A*02:01 470 SLSRFSWGA Myelin basic protein 110-118
A*02:01 1904 VLFGLGFAI T1D Diabetes IGRP 265-273
A*02:01 2259 ALWGPDPAAA Proinsulin precursor 15-24
A*02:01 3342 YTCPLCRAPV SSA SS-56 55-64
A*02:01 2382 MVWESGCTV IA-2 797-805
A*02:01 3394 VIVMLTPLV IA-2 805-813
H-2Db 1107 RSPFSRVVHL MOG Precursor 69-78


(back to top)

Cancer

Publications Citing Cancer Pentamers
Case Studies of Customer
Research into Cancer

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*01:01 29 EADPTGHSY MAGE-A1 161-169
A*01:01 30 EVDPIGHLY MAGE-A3 168-176
A*01:01 307 KSDICTDEY Tyrosinase 243-251 (244S)
A*01:01 467 KCDICTDEY Tyrosinase 243-251
A*01:01 1542 QSLEIISRY Mcl-1 177–185
A*01:01 2102 YVDFREYEYY FLT3 ITD
A*01:01 3383 TLDTLTAFY Mesothelin 429-437
A*01:01 3622 LTDDRLFTCY PLEKHM2
A*01:01 3623 DSDPDSFQDY Tyr A1a 454-463
A*01:01 3624 EADPIGHLY MAGEA3
A*01:01 3626 EVDPASNTY MAGE-A4 169–177
A*01:01 3627 HSTNGVTRIY PSMA
A*01:01 3628 ILDTAGREEY N-ras 55-64
A*01:01 3630 LVDVMPWLQY Cytochrome P450 240-249
A*01:01 3632 RSDSGQQARY AIM-2
A*01:01 3633 VTEPGTAQY Minor antigen HA-3T (Lbc oncogene 451-459)
A*01:01 3634 VYDFFVWLHY TRP-2 181-190
A*02:01 34 FLWGPRALV MAGEA3 271-279
A*02:01 46 IMDQVPFSV gp100 (pmel17) 209-217
A*02:01 47 YLEPGPVTV gp100 (pmel) 280-288 (288V)
A*02:01 48 YLSGADLNL Carcinoembryonic antigen (CEA)-derived peptide CAP1-6D
A*02:01 49 SLLMWITQC NY-ESO-1 157-165 (9C)
A*02:01 57 KTWGQYWQV gp100 (pmel17) 154-162
A*02:01 58 YLEPGPVTA gp100
A*02:01 61 YMDGTMSQV Tyrosinase 369-377 (371D)
A*02:01 75 YLSGANLNL Carcinogenic Embryonic Antigen (CEA) 571-579
A*02:01 82 ELAGIGILTV MelanA / MART 26-35
A*02:01 85 ILAKFLHWL Telomerase 540-548
A*02:01 86 ALQPGTALL Prostate Stem Cell Antigen (PSCA) 14-22
A*02:01 97 VISNDVCAQV Prostate Specific Antigen-1 (PSA-1) 154-163
A*02:01 117 RLVDDFLLV Telomerase Reverse Transcriptase 865-873
A*02:01 125 GVLVGVALI Carcinogenic Embryonic Antigen (CEA) 694-702
A*02:01 157 VLYRYGSFSV gp100 (pmel17) 476-485
A*02:01 162 PLFQVPEPV Alpha-fetoprotein isoform 1 137-145
A*02:01 163 FMNKFIYEI Human alfa fetoprotein 158-166
A*02:01 164 GLSPNLNRFL Alpha-fetoprotein isoform 2 167-176
A*02:01 171 KVLEYVIKV MAGEA1 278-286
A*02:01 205 LLGRNSFEV p53 264-272
A*02:01 208 LLLLTVLTV MUC-1 12-20
A*02:01 210 ILHNGAYSL HER-2/neu 435-443
A*02:01 212 RLLQETELV HER-2/neu 689-697
A*02:01 214 KIFGSLAFL HER-2/neu 369-377
A*02:01 220 LLLLDVAPL HSP1A 459-467
A*02:01 221 LLDVAPLSL HSP1A 461-469
A*02:01 226 HLYQGCQVV Receptor tyrosine-protein kinase erbB-2 48-56
A*02:01 249 HLSTAFARV G250 (renal cell carcinoma) 217-225
A*02:01 250 VLQELNVTV Leukocyte Proteinase-3 (Wegener’s autoantigen) 169-177
A*02:01 302 KVAELVHFL MAGEA3 112-120
A*02:01 304 VLAGVGFFI EPHA2 550-558
A*02:01 306 FLYTLLREV STEAP 86-94
A*02:01 329 ILLWQPIPV Prostatic Acid Phosphatase-3 (PAP-3) 135-143
A*02:01 337 RLQEERTCKV BIR
A*02:01 338 QLCPICRAPV Livin/ML-IAP280 175-184
A*02:01 345 VLGEAWRDQV TRAP 45-54
A*02:01 381 LLLTVLTVV Tumor Mucin Antigen 13-21
A*02:01 389 GLYDGMEHL MAGEA-10 254-262
A*02:01 390 SLLMWITQV NY-ESO-1 157-165
A*02:01 391 LMLGEFLKL Survivin 96-104
A*02:01 394 YLFFYRKSV mTERT 572-580
A*02:01 400 ELTLGEFLKL survivin 95-104
A*02:01 404 FLTPKKLQCV Prostate Specific Antigen-1 (PSA-1) 141-150
A*02:01 405 KLQCVDLHV Prostate Specific Antigen 146-154
A*02:01 408 TLAPATEPA Mucin 79-87
A*02:01 447 YLQVNSLQTV Telomerase Reverse Transcriptase (hTRT) 988-997
A*02:01 452 SLGEQQYSV WT1 187-195
A*02:01 457 SLEENIVIL RHAMM 275-283
A*02:01 464 YMNGTMSQV Tyrosinase 368-376
A*02:01 468 ILSLELMKL Receptor for hyaluronic acid–mediated motility (RHAMM) 165-173
A*02:01 480 PLFDFSWLSL Bcl-2 208-217
A*02:01 516 LLGATCMFV CyclinD 101-109
A*02:01 527 ALYVDSLFFL PRAME PRA 300–309
A*02:01 543 ALCNTDSPL iLR1
A*02:01 550 ALKDVEERV MAGE-C2 336-344
A*02:01 560 GLMEEMSAL Human Mena protein (overexpressed in breast cancer)
A*02:01 561 TMNGSKSPV hMena 502-510
A*02:01 575 GVYDGREHTV MAGE-A4 230–239
A*02:01 594 YLNDHLEPWI Bcl-X 173-182
A*02:01 599 ALDVYNGLL Prostatic acid phosphatase precursor (PAP) 299-307
A*02:01 600 ALFDIESKV PSM P2 (prostate)
A*02:01 628 LLAARAIVAI iLR1 59-68
A*02:01 637 SLAMLDLLHV Mutant anaplastic lymphoma kinase 1220-1229
A*02:01 645 YLNTVQPTCV EGF-R 1138-1147
A*02:01 646 KLFGTSGQKT EGF-R-479 350-359
A*02:01 654 RMPEAAPPV p53 65-73
A*02:01 662 PLTSIISAV Receptor tyrosine-protein kinase erbB-2 728-736
A*02:01 689 VLAGGFFLL PSMA 27-38
A*02:01 690 LLHETDSAV PSMA/PSM-P1 4-12
A*02:01 693 VMAGVGSPYV Receptor tyrosine-protein kinase erbB-2 819-828
A*02:01 773 VLPLTVAEV Mesothelin 530–538
A*02:01 774 SLLFLLFSL Mesothelin 20-28
A*02:01 780 QLFEELQEL Heme oxygenase-1 212-220
A*02:01 781 VLDGLDVLL PRAME 100-108
A*02:01 787 RLASFYDWPL BIR7 90-99
A*02:01 810 LIAHNQVRQV HER-2/neu (85–94)
A*02:01 811 ILHDGAYSL HER-2 434-443
A*02:01 813 FVGEFFTDV GPC3 144-152 (overexpressed in hepatocellular carcinoma)
A*02:01 841 LLLIWFRPV BKV Ltag 579-587
A*02:01 859 KLQDASAEV HM1.24-aa 126-134
A*02:01 860 SLYSFPEPEA PRAME
A*02:01 861 SLLQHLIGL PRAME 425-433
A*02:01 862 VIFDFLHCI BKV Ltag 406-414
A*02:01 884 RLWQELSDI circadian clock protein PASD1 691-700
A*02:01 893 VLDFAPPGA WT1
A*02:01 915 TLPGYPPHV PAX-5 311-319
A*02:01 921 YMEHNNVYTV Fibromodulin 250-259
A*02:01 922 YLQHNEIQEV Fibromodulin 206-215
A*02:01 958 SLVDVMPWL Cytochrome p450 1B1 239-248
A*02:01 960 RLMNDMTAV HSP105 128-136
A*02:01 997 RLARLALVL Trophoblast glycoprotein 17-25
A*02:01 998 FLTGNQLAV 5T4 97–105
A*02:01 1007 LLLAGLFSL Fibromodulin 7-15
A*02:01 1013 FLGYLILGV Prostatic Acid Phosphatase-3 (PAP-3)
A*02:01 1056 SLFLGILSV CD20 188-196 (B cell malignancies)
A*02:01 1130 AVLPLLELV MCL-1 139-147
A*02:01 1181 SLSEKTVLL CD59 glycoprotein precursor 106-114
A*02:01 1201 YMCSFLFNL Ewing Tumor EZH2 666-674
A*02:01 1239 YLISGDSPV CD33 65-73 (1Y2L)
A*02:01 1246 KASEKIFYV SSX2 41-49
A*02:01 1302 FLAKLNNTV HCA587 317-325
A*02:01 1303 LLFGLALIEV MAGE-C2 191-200
A*02:01 1386 GLAPPQHLIRV p53 187-197
A*02:01 1403 VIMPCSWWV Chondromodulin-I 319-327
A*02:01 1421 KVVEFLAML MAGE-C1 1083-1091
A*02:01 1464 LTLGEFLKL Survivin-3A 96-104
A*02:01 1508 ALPFGFILV IL13R 345-353
A*02:01 1509 TLADFDPRV EphA2
A*02:01 1778 ALMEQQHYV ITGB8 662-670
A*02:01 1779 CLTSTVQLV HER-2/neu 789-797
A*02:01 1786 GLLGASVLGL Telomerase Reverse Transcriptase (hTRT) 674-683
A*02:01 1908 QLLDGFMITL PASD1 39-48
A*02:01 1910 YLVGNVCIL PASD1 168-176
A*02:01 1920 ALLTSRLRFI Telomerase Reverse Transcriptase (hTRT) 615-624
A*02:01 1937 RLSSCVPVA 131-139
A*02:01 2079 FLYDDNQRV Topoisomerase II-alpha-b 828-836
A*02:01 2081 YLIELIDRV TACE 250-258
A*02:01 2083 FLAEDALNTV Epithelial Discoidin Domain Receptor 1 (EDDR1) 867-876
A*02:01 2103 YMLDLQPET E7 11-19
A*02:01 2236 GLMKYIGEV TRPM8 187-195
A*02:01 2282 FLDPRPLTV CYP190
A*02:01 2291 AILALLPAL Prostate Stem Cell Antigen (PSCA) 105-133
A*02:01 2293 GLQHWVPEL BA46 (Lactadherin) 97-106
A*02:01 2294 GVRGRVEEI BCR-ABL
A*02:01 2296 ITDQVPFSV gp100 (pmel) 209-217
A*02:01 2297 KLCPVQLWV p53 139-147
A*02:01 2298 KVAEELVHFL MAGEA3 112-120 (alternative version)
A*02:01 2299 SLPPPGTRV p53 149-157
A*02:01 2300 YLGSYGFRL p53 103-111
A*02:01 2301 YLQLVFGIEV MAGEA2 157-166
A*02:01 2371 TLQDIVYKL BMI1 74-82
A*02:01 2457 YAIDLPVSV L-dopachrome tautomerase 488-496
A*02:01 2569 AMVGAVLTA Tyrosinase 482-190
A*02:01 2582 ATVGIMIGV CEACAM5 687-695
A*02:01 2649 YVDPVITSI Hepatocyte growth factor receptor 673-681
A*02:01 2669 GVLLWEIFSL VEGFR1 28-37
A*02:01 2793 LMAQEALAFL CAMEL 2-11
A*02:01 2988 RVA(PHOSPHO-S)PTSGV Insulin receptor substrate-2 1097-1105
A*02:01 2990 RVASPTSGV IRS-2 1097-1105
A*02:01 3343 ALNVYNGLL ACPP 299-307
A*02:01 3344 ALSPVPPVV Bcl-2 85-93
A*02:01 3345 ALVCYGPGI FAP alpha 463-471
A*02:01 3346 ALWPWLLMAT RNF43 11-20
A*02:01 3347 ALYLMELTM CB9L2
A*02:01 3350 CLPSPSTPV BMI1 271-279
A*02:01 3352 ELSDSLGPV PASD1 695-703
A*02:01 3355 FLFLRNFSL TARP(V28L)27-35
A*02:01 3356 FLPSPLFFFL TARP(P5L) 5-13
A*02:01 3357 GLFKCGIAV FAP 639-647
A*02:01 3358 GLIQLVEGV TRAG-3 4-12
A*02:01 3361 ILGVLTSLV DLK1 309-317
A*02:01 3363 LLVPTCVFLV 691-700
A*02:01 3365 MLAVFLPIV STEAP 292-300 (293L)
A*02:01 3366 NLFETPVEA 194-202
A*02:01 3368 QLGEQCWTV PSCA 44-51 (51A)
A*02:01 3371 RLAEYQAYI SART3 309-317
A*02:01 3374 SIDWFMVTV p31-39
A*02:01 3375 SILLRDAGLV TRAG-3 57-66
A*02:01 3377 SLFEPPPPG PSMA 85-93
A*02:01 3379 SQADALKYV EZH2 729-737
A*02:01 3386 WLSLKTLLSL Bcl-2 214-223
A*02:01 3387 YLNRHLHTWI BCL-2 180-189
A*02:01 3388 YLQWIEFSI Prominin1 744-752
A*02:01 3389 YLYQWLGAPV Osteocalcin 51-60
A*02:01 3416 KLMSSNSTDL HSP105 234-243
A*02:01 3418 STLCQVEPV MPP11
A*02:01 3419 VLQMKEEDV iLR1
A*02:01 3420 AIQDLCLAV NPM1
A*02:01 3421 QLLIKAVNL MPP11
A*02:01 3422 AIQDLCVAV NPM1
A*02:01 3423 ALTPVVVTL cyclin-dependent kinase 4 170-178
A*02:01 3436 RLQGISPKI SSX2 103-111
A*02:01 3636 AILALLPALL PSCA
A*02:01 3638 ALIHHNTHL HER2 466-474
A*02:01 3641 CMHLLLEAV MG50 624–632
A*02:01 3643 FLIIWQNTM FSP26
A*02:01 3644 FLPWHRLFLL Tyrosinase 207-216
A*02:01 3647 FVWLHYYSV TRP2 185-193(L)
A*02:01 3648 GLFGDIYLA CSNK1A1 26-34
A*02:01 3649 GLFGDIYLAI CSNK1A1 26-35
A*02:01 3654 ILLRDAGLV TRAG-3L 58-66
A*02:01 3655 ILLVVVLGV Receptor tyrosine-protein kinase erbB-2 707-715
A*02:01 3656 ILNAMIAKI HAUS3 154-162
A*02:01 3658 KASEYLQLV MAGEA2 153-161
A*02:01 3659 KIWEELSVL MAGEA3 220-228
A*02:01 3660 KLIDRTE(S)L LSP1 325-333
A*02:01 3661 KLTGDENFTI Tyrosinase precursor 224-233
A*02:01 3662 LLCYSCKAQV PSCA 17-26
A*02:01 3666 LLLEAVPAV MG50 69-77
A*02:01 3668 LLNQLQVNL Mucin2 467-475
A*02:01 3669 LLRDAGLVKM TRAP 59-68
A*02:01 3670 LLRRYNVAKV SOX11 266-275
A*02:01 3671 LLSHGAVIEV Ankyrin NYBR1 158-167
A*02:01 3673 LVFGIELMEV MAGEA3 160-169
A*02:01 3674 LVFGIEVVEV MAGEA12 160-169
A*02:01 3675 MLWGWREHV Mucin2 645-653
A*02:01 3676 NLVKQKPQI Alpha-fetoprotein isoform 1 555-563
A*02:01 3678 PLQPEQLQV Receptor tyrosine-protein kinase erbB-2 437-445
A*02:01 3680 QLMAFNHLI PAX3/FKHR 135-143
A*02:01 3681 QLMPYGCLL Receptor tyrosine-protein kinase erbB-2 845-853
A*02:01 3684 RLGPTLMCL MG50 1244-1252
A*02:01 3687 RLTRFLSRV CyclinD 228-236
A*02:01 3688 RTF(S)PTYGL Desmuslin 426-434
A*02:01 3689 SILLRDAGL TRAP 57-65
A*02:01 3691 SLADEAEVYL GAS7 Neoepitope
A*02:01 3693 SLDDYNHLV L-dopachrome tautomerase 288-296
A*02:01 3695 SLYKFSPFPL O-linked N-acetylglucosamine transferase FSP06
A*02:01 3696 SMTR(S)PPRV SFRS2B 241-249
A*02:01 3698 TLEEITGYL Receptor tyrosine-protein kinase erbB-2 448-456
A*02:01 3699 TLHCDCEIL MG50 210-218
A*02:01 3700 TMKQEFLINL Alpha-fetoprotein isoform 1 547-556
A*02:01 3702 VLEPPGARDV BIR 7 230-239
A*02:01 3704 VLLALLMAGL Prostate stem cell antigen 4-13
A*02:01 3705 VLSVNVPDV MG50 625-633
A*02:01 3706 VLVKSPNHV Receptor tyrosine-protein kinase erbB-4 890-898
A*02:01 3708 VMIG(S)PKKV Tensin3 1558-1566
A*02:01 3709 VVLGVVFGI Receptor tyrosine-protein kinase erbB-2 743-751
A*02:01 3710 WLPKILGEV MG50 1051-1059
A*02:01 3711 WLQYFPNPV Cytochrome P450 246-254
A*02:01 3713 YLLDLSTNHL Fibromodulin 7-15
A*02:01 3715 YLWWVNNQSL CEA 176-185
A*02:01 3718 ALGGHPLLGV Dickkopf-related protein 1 20-29
A*02:01 3719 ALLAGLVSL FGFR4 676-684
A*02:01 3720 ALLTYMIAHI Thymidylate synthase 231-240
A*02:01 3721 ALMDKSLHV MART-1 56-64
A*02:01 3722 ALPPPLMLL Heparanase 8-16
A*02:01 3723 ALSVMGVYV MAGEA9 223-231
A*02:01 3724 ALVEFEDVL hnRNP L 140-148
A*02:01 3725 ALWPWLLMA RNF43 11-19
A*02:01 3726 AMLGTHTMEV Melanocyte-specific secreted glycoprotein 184-193
A*02:01 3728 AVIGALLAV Melanocyte-specific secreted glycoprotein 20-28
A*02:01 3730 CLYGNVEKV hnRNP L 404-412
A*02:01 3731 DLIFGLNAL Heparanase 185-193
A*02:01 3732 ELFQDLSQL ETV5 54-53
A*02:01 3733 FAWERVRGL Cyclin-dependent kinase inhibitor 1 97-105
A*02:01 3734 FIASNGVKLV ACTN4 118-127 (K5N)
A*02:01 3735 FLALIICNA Tubulin beta 4 283-291
A*02:01 3736 FLDEFMEGV Malic enzyme 224-232
A*02:01 202A RMFPNAPYL WT-1 126-134 (Wilms tumor)
A*03:01 87 KQSSKALQR bcr-abl 210 kD fusion protein 21-29
A*03:01 118 ALLAVGATK gp100 (pmel17) 17-25
A*03:01 264 ATGFKQSSK bcr-abl 210 kD fusion protein 259-269
A*03:01 541 RISTFKNWPK Survivin-3A 18-27 (27K)
A*03:01 552 RLGLQVRKNK RhoC 176-185 (177L)
A*03:01 615 RLLFFAPTR Mcl-1 95-103
A*03:01 3369 QVLKKIAQK HMOX1 145-153
A*03:01 3370 RIAAWMATY 165-173
A*24:02 209 TYACFVSNL Carcinogenic Embryonic Antigen (CEA) 652-660
A*24:02 230 AFLPWHRLF Tyrosinase 188-196
A*24:02 237 IMPKAGLLI MAGE-A3
A*24:02 238 VYFFLPDHL gp100-intron 4 (170-178)
A*24:02 416 EYLQLVFGI MAGEA2 156-164
A*24:02 417 TYLPTNASL HER-2/neu 63-71
A*24:02 418 VYGFVRACL Telomerase reverse transcriptase (hTRT) 461-469
A*24:02 421 TFPDLESEF MAGEA3 97-105
A*24:02 1064 DYLQYVLQI MiHA ACC1 15-23
A*24:02 1806 RYCNLEGPPI Lymphocyte antigen 6 complex locus K (LY6K) 177-186
A*24:02 2302 AYACNTSTL Survivin 80-88
A*24:02 2303 CYASGWGSI Prostate Specific Antigen-1 153-161
A*24:02 3351 DYLNEWGSRF CDH3 807-816
A*24:02 3353 EYCPGGNLF MELK 87-95 (93N)
A*24:02 3354 EYYELFVNI DEP DC1 294-302
A*24:02 3360 GYCTQIGIF HENMT1 221-229
A*24:02 3362 IYTWIEDHF FOXM1 262-270
A*24:02 3367 NYQPVWLCL RNF43 721-729 (722Y)
A*24:02 3372 RYNAQCQETI Midkine 110-119
A*24:02 3380 EYRALQLHL CA9 219-227
A*24:02 3382 SYRNEIAYL TTK protein kinase 551-559
A*24:02 3384 VYLRVRPLL KIF20A 67-75
A*24:02 3385 VYYNWQYLL IL13r 146-154
A*29:02 3397 KEKYIDQEEL HSP90 alpha 280-288 (Pathologic Conditions)
A*68:01 3398 TVSGNILTIR NY-ESO-1 127-136
B*07:02 2304 LPWHRLFLL Tyrosinase 208-216
B*07:02 2369 EPR(PHOSPHO-S)PSHSM Insulin receptor substrate 2
B*07:02 3239 TPNQRQNVC P2X5
B*07:02 3348 APRGVRMAV LAGE-1 46-54
B*07:02 3364 LPVSPRLQL CEACAM 185-193
B*07:02 3378 SPFFLLLLL Tumor Mucin antigen 7-15
B*08:01 94 GFKQSSKAL bcr-abl 210 kD fusion protein 19-27
B*27:05 424 GRFGLATEK BRAF 594-601 (600E)
B*27:05 3359 GRFGLATVK BRAF 594-601 (600V)
B*27:05 202B RMFPNAPYL WT-1 126-134 (Wilms tumor)
B*35:01 2307 MPFATPMEA NY-ESO-1 94-102
H-2Db 231 CMTWNQMNL WT1 235-243
H-2Db 559 HCIRNKSVI PSA 65-73
H-2Db 695 Abu-Abu-L-Abu-LTVFL Moloney murine sarcoma virus (MoMSV) GagL 85–93
H-2Db 1333 KVPRNQDWL gp100 (pmel17) 25-33
H-2Db 1731 ATFKNWPFL Murine Survivin 20-28
H-2Db 1780 HCIRNKSVIL hPSA
H-2Db 2198 VILTNPISM VEGFR2 400-408
H-2Db 2199 FSNSTNDILI VEGFR2/KDR fragment 1 614-624
H-2Db 2695 ASMTNMELM MC28 adpgk neoantigen
H-2Db 2755 AQLANDVVL MC-38
H-2Db 3349 ASFRNLTHL TPBG 258-266
H-2Db 202C RMFPNAPYL WT-1 126-134 (Wilms tumor)
H-2Kb 185 SVYDFFVWL Tyrosinase related protein-2 180-188
H-2Kb 351 HNTQYCNL MAGEA5 5-12
H-2Kb 2311 TVSEFLKL Murine Survivin 97-104
H-2Kb 2585 VGRNFTNL mTERT
H-2Kb 2754 SIIVFNLL MC-38
H-2Kb 3373 SDYYFSWL muFAP 289-296
H-2Kb 3376 SKYVFENV Mybpc2 295-302
H-2Kd 275 DYWGQGTEL Surface IgG (sA20-Ig) of A20 106-114
H-2Kd 343 TYVPANASL Neu/Her-2/Erbb2 proto-oncoprotein 66-74
H-2Kd 485 AYIDFEMKI SART3 315-323
H-2Kd 814 EYILSLEEL GPC3 298-306
H-2Kd 3381 SYMLQALCI TNPO3
H-2Kk 825 FETFEAKI T3H 104-111
H-2Ld 150 LPYLGWLVF Tumour Antigen P815 35-43


(back to top)

Chlamydia

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 334 RLNMFTPYI Chlamydia trachomatis MOMP 258-266


(back to top)

CMV


Publications citing CMV Pentamers

Case Studies of Customer Research
into CMV

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*01:01 739 VTEHDTLLY HCMV pp50 245-253
A*01:01 266 YSEHPTFTSQY HCMV pp65 363-373
A*02:01 008 NLVPMVATV HCMV pp65 495-504
A*02:01 1598 VLAELVKQI HCMV IE1 81-89
A*02:01 2205 MLNIPSINV pp65 120-128
A*02:01 144 VLEETSVML HCMV IE1 316-324 (UL123)
A*03:01 1599 KLGGALQAK HCMV IE1 184-192
A*24:02 414 QYDPVAALF HCMV pp65 341-349
A*24:02 380 VYALPLKML HCMV pp65 113-121
A*24:02 3390 AYAQKIFKI CMV IE-1 248-256
B*07:02 308 RPHERNGFTVL HCMV pp65 265-275
B*07:02 045 TPRVTGGGAM HCMV pp65 417-426
B*08:01 127 ELRRKMMYM IE1 199-207
B*08:01 3391 ELKRKMIYM CMV IE-1 199-207 (R/L Position 3, M/I Position 7)
B*35:01 114 IPSINVHHY HCMV pp65 123-131
H-2Db 2313 HGIRNASFI MCMV m45 985-993
H-2Dd 278 AGPPRYSRI MCMV m164 257-265
H-2Dd 2167 LGPISGHVL pp65 15-23
H-2Kb 1915 TVYGFCLL MCMV M139 419-426
H-2Kb 3413 VIDAFSRL MCMV M141 15-23
H-2Kd 3412 CYYASRTKL MCMV m145 451-459
H-2Ld 021 YPHFMPTNL MCMV IE1 168-176


(back to top)

EBV

Publications citing EBV Pentamers
Case Studies of Customer Research
into EBV

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 042 CLGGLLTMV EBV LMP-2 426-434
A*02:01 001 GLCTLVAML EBV BMLF-1 259-267
A*02:01 666 FLYALALLL EBV LMP-2 356-364
A*02:01 409 YLLEMLWRL EBV LMP-1 125-133
A*02:01 2292 FLDKGTYTL EBV BALF-4 276–284
A*02:01 462 YVLDHLIVV BRLF1 109–117
A*02:01 410 YLQQNWWTL LMP1 159-167
A*02:01 1616 LLDFVRFMGV EBV EBNA-3C 284-293
A*02:01 872 TLDYKPLSV EBV BMRF1 208-216
A*03:01 727 RLRAEAQVK ENV EBNA 3A 603–611
A*03:01 1838 RVRAYTYSK BRLF1
A*11:01 199 IVTDFSVIK EBV EBNA-4 416-424
A*11:01 508 SSCSSCPLSK EBV LMP-2 340-349
A*11:01 639 ATIGTAMYK EBV BRLF1 134-142
A*11:01 726 AVFDRKSDAK EBNA3B 399-408
A*24:02 420 TYGPVFMCL EBV LMP-2 419-427
A*24:02 648 PYLFWLAAI EBV LMP2 131-139
A*24:02 683 TYGPVFMSL EBV LMP2 419–427
B*07:02 044 RPPIFIRRL EBV EBNA-3A 247-255
B*07:02 2305 QPRAPIRPI EBV EBNA-3C 881-889
B*07:02 647 RPQGGSRPEFVKL EBV BMRF1 116-128
B*08:01 073 FLRGRAYGL EBV EBNA-3A 193-201
B*08:01 190 RAKFKQLL EBV BZLF-1 190-197
B*08:01 489 QAKWRLQTL EBV EBNA3A 158-166
B*35:01 399 EPLPQGQLTAY EBV BZLF-1 54-64
B*35:01 3033 HPVAEADYFEY EBV EBNA-1 407-417(4A)
B*35:01 107 YPLHEQHGM EBV EBNA-3A 458-466
B*40:01 692 IEDPPFNSL EBV LMP2 200-208


(back to top)

HBV

Publications citing HBV Pentamers
Case Studies of Customer
Research into Hepatitis

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 032 FLLSLGIHL HBV polymerase 573-581
A*02:01 027 FLLTRILTI HBV envelope 183-191
A*02:01 023 FLPSDFFPSV HBV core antigen 18-27
A*02:01 028 GLSPTVWLSV HBV surface antigen 185-194
A*02:01 031 WLSLLVPFV HBV surface antigen 172-181
A*02:01 283 FLPSDFFPSI HBV core 18-27 (subtype ADR4)
A*02:01 2829 KLHLYSHPI Pol 502-510
A*11:01 377 YVNVNMGLK HBV core antigen 88-96
A*24:02 378 EYLVSFGVW HBV core 117-125
A*24:02 413 KYTSFPWLL HBV polymerase 756-764
H-2Kb 422 ILSPFLPLL HBV surface antigen 208-216
H-2Kb 1431 MGLKFRQL HBV core 93-100
H-2Kb 477 VWLSVIWM HBV Surface antigen 190-197
H-2Ld 129 IPQSLDSWWTSL HBV surface antigen 28-39


(back to top)

HCV


Publications citing HCV Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*01:01 740 ATDALMTGY HCV NS3 1435-1443
A*01:01 1066 ATDALMTGF HCV NS3 1436-1444
A*02:01 003 CINGVCWTV HCV NS3 1073-1081
A*02:01 002 DLMGYIPAV HCV core 132-140
A*02:01 040 KLVALGINAV HCV NS3 1406-1415
A*02:01 491 DLMGYIPLV HCV core 132-140
A*02:01 4 YLLPRRGPRL HCV core 35-44
A*02:01 1094 GLQDCTMLV HCV NS5B 2727-2735
A*02:01 242 KLSGLGINAV HCV NS3 1406-1415
A*02:01 172 LLFNILGGWV HCV NS4b 1807-1816
A*02:01 36 VLSDFKTWL HCV NS5a 1987-1995
A*02:01 858 CVNGVCWTV HCV NS3 1073-1081
A*02:01 037 ALYDVVTKL HCV NS5b 2594-2602
A*02:01 778 GLSRYVARL HCV Pol 455-463
A*03:01 035 RVCEKMALY HCV NS5B 2588-2596
A*24:02 415 AYSQQTRGL HCV NS3 1031-1039
B*07:02 742 GPRLGVRAT HCV core 41-49
B*07:02 845 DPRRRSRNL HCV core 111-119
B*08:01 721 HSKKKCDEL HCV NS3 1395-1403
B*27:05 871 ARMILMTHF NS5B 2841-2849
B*35:01 565 HPNIEEVAL HCV NS3 1359-1367
B*35:01 942 CPNSSIVY HCV E1 207-214
B*40:01 939 REISVPAEIL HCV NS5a 2266-2275
H-2Db 791 GAVQNEVTL HCV NS3 1629-1637


(back to top)

HIV/SIV

Publications citing HIV Pentamers
Case Studies of Customer Research
into HIV

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 084 ILKEPVHGV HIV-1 RT 476-484
A*02:01 246 KLTPLCVTL HIV-1 env gp120 90-98
A*02:01 010 SLYNTVATL HIV-1 gag p17 76-84
A*02:01 174 TLNAWVKVV HIV-1 gag p24 19-27
A*02:01 430 GLADQLIHL HIV-1 Vif 101-109
A*02:01 799 LTFGWCFKL HIV-1 Nef 137-145
A*02:01 1240 ALVEMGHHA HIV Vpu 66-74
A*02:01 1147 FLGKIWPS Gag 433-440
A*02:01 1244 NVWATHACV HIV Env gp 67-7
A*02:01 1241 RTLNAWVKV HIV Gag 150-158
A*02:01 3401 SLFNTVATL HIV gag 77-85
A*02:01 1537 SLLNATAIAV HIV env 816-825
A*02:01 3402 SLVKHHMYI HIV Vif 23-31
A*02:01 3403 VIYHYVDDL HIV Pol
A*03:01 109 QVPLRPMTYK HIV-1 nef 73-82
A*03:01 194 RLRPGGKKK HIV-1 gag p17 19-27
A*03:01 1496 AIFQSSMTK HIV pol 325-333
A*11:01 1486 AVDLSHFLK HIV nef 84-92
A*11:01 1686 ACQGVGGPGHK HIV gag p24
A*24:02 419 RYLKDQQLL HIV-1 gag gp41 67-75
A*24:02 411 RYPLTFGWCY HIV-1 Nef 134-143
A*24:02 1805 RYLRDQQLL HIV env
A*24:02 3238 RYPLTFGW HIV nef
A*24:02 3099 RYPLTFGWCF HIV NEF 143-152
A*29:02 3392 LYNTVATLY HIV gag 79-86
A*29:02 3395 SFDPIPIHY HIV env 216-224
A*29:02 3396 SFNCRGEFFY HIV env 382-391
B*07:02 196 IPRRIRQGL HIV-1 env gp120 848-856
B*07:02 257 TPGPGVRYPL HIV-1 nef 128-137
B*07:02 877 GPGHKARVL HIV gag p24 223–231
B*08:01 193 FLKEKGGL HIV-1 nef 90-97
B*08:01 195 GEIYKRWII HIV-1 gag p24 261-269
B*08:01 879 EIYKRWII HIV p24 gag 128-135
B*08:01 1536 YLKDQQLL Env 586-593
B*15:01 1072 RLRPGGKKKY HIV-1 p17 20-29
B*27:05 294 KRWIILGLNK HIV-1 gag p24 265-274
B*27:05 874 KRWIIMGLNK HIV-1 Gag p24 263-272
B*27:05 2306 GRAFVTIGK HIV-1 gp100 103-111
B*35:01 255 NPDIVIYQY HIV-1 RT 330-338
B*35:01 255 NPDIVIYQY HIV-1 HIV-1 RT 328-336
B*35:01 1211 VPLDEDFRKY HIV-1 HIV-1 RT 273-282
B*40:01 840 KEKGGLEGL HIV-1 Nef 92-100
H-2Db 719 AAVKNWMTQTL SIV gag
H-2Dd 177 RGPGRAFVTI HIV-1 IIIB gp120 318-327
H-2Dd 1684 IGPGRAFYA HIV-1 US4 gp120 318-326
H-2Kd 176 AMQMLKETI HIV-1 gag p24 199-207
H-2Kd 403 AMQMLKDTI HIV gag p24 197-205
Mamu-A*01 1110 CTPYDINQM SIV Gag 181-189
Mamu-A*02 1111 YTSGPGIRY SIV Nef 159-167
Mamu-A*02 1112 GSENLKSLY SIV Gag 71-79


(back to top)

HPV

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 095 YMLDLQPETT HPV 16 E7 11-20
A*02:01 2312 MLDLQPETT HPV 16 E7 12-20
A*02:01 658 KLPQLCTEL HPV 16 E6 18-26
A*03:01 2064 KLCLRFLSK HPV 33 E6 64-72
A*11:01 2067 NTLEQTVKK HPV 33E6 86-94
A*24:02 3240 VYDFAFRDL HPV16 E6
B*07:02 2065 KPTLKEYVL HPV 33 E7 5-13
H-2Db 502H RAHYNIVTF HPV 16 E7 49-57
H-2Db 3404 AGVDNRECI HPV L1 165-173
H-2Kb 2560 EVYDFAFRDL HPV E6 48-57


(back to top)

HSV

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 1152 VLMIKALEL Non muscle Myosin-9 741-749
A*02:01 1153 QLFNHTMFI Non-muscle Myosin 478-486
A*02:01 3406 QMARLAWEA 1116-1124
H-2Db 3405A AGPHNDMEI HSV p56 487-495
H-2Dd 3405B AGPHNDMEI HSV p56 487-495
H-2Kb 188 SSIEFARL HSV-1 gp B 498-505
H-2Kd 3407 TYWPVVSDI 207-215


(back to top)

HTLV

Publications citing HTLV Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 200 LLFGYPVYV Human T-cell lymphotropic virus-1 (HTLV-1) tax 11-19
A*02:01 2309 AVLDGLLSL HTLV bZIP factor 42-50
A*02:01 3408 GLLSLEEEL bZIP factor 26-34
A*24:02 1043 SFHSLHLLF HTLV Tax 301-309
B*07:02 3400 LPVSCPEDL bZIP factor 10-18


(back to top)

Influenza

Publications citing Influenza Pentamers
Case Studies of Customer
Research into Influenza

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*01:01 076 CTELKLSDY Influenza A (PR8) NP 44-52
A*01:01 540 VSDGGPNLY Influenza A PB1 591-599
A*02:01 007 GILGFVFTL Influenza A MP 58-66
A*02:01 2295 ILGFVFTLTV Influenza A MP 59-68
A*02:01 3409 KLGEFYNQMM Flu BNP 85-94 (Influenza B)
A*03:01 077 ILRGSVAHK Influenza A (PR8) NP 265-274
A*11:01 1722 KSMREEYRK Influenza A MP2 70-78
A*11:01 1720 RMVLASTTAK Influenza A MP1 178-187
A*11:01 1513 SIIPSGPLK Influenza A MP 13-21
B*07:02 1743 QPEWFRNVL Influenza A PB1 329-337
B*07:02 1744 SPIVPSFDM Influenza A NP 473-481
B*27:05 463 SRYWAIRTR Influenza A NP 383-391
H-2Db 009 ASNENMDAM Influenza A (NT60) NP 366-374
H-2Db 119 ASNENMETM Influenza A (PR8) NP 366-374
H-2Db 3410 SCLENFRAYV Influenza A polymerease PA 224-233
H-2Db 120 SSLENFRAYV Influenza A (PR8) Polymerase acidic protein 224-233
H-2Kd 240 IYSTVASSL Influenza A HA 533-541
H-2Kd 098 TYQRTRALV Influenza A (PR8) NP 147-155


(back to top)

JC Virus

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 611 ILMWEAVTL VP1 100-108
A*02:01 610 SITEVECFL VP1 36-44


(back to top)

LCMV

Publications citing LCMV Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 2308 ALPHIIDEV LCMV envelope gp 10-18
A*02:01 2310 YLVSIFLHL LCMV envelope gp 447-455
A*02:01 3411 SLNQTVHSL NP 69-77
H-2Kb 2076 ISHNFCNL LCMV GP 118-125
H-2Db 070 FQPQNGQFI LCMV NP 396-404
H-2Db 069 KAVYNFATC LCMV GP1 33-41
H-2Db 186 SGVENPGGYCL LCMV GP 276-286
H-2Db 142 KAVYNFATM gp33 (C9M)


(back to top)

Listeria

Publications citing Listeria Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
H-2Kd 178 GYKDGNEYI Listeria monocytogenes Listeriolysin 91-99


(back to top)

Malaria

Publications citing Malaria Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*02:01 314 YLNKIQNSL Plasmodium falciparum CSP 334-342
H-2Db 2697 SQLLNAKYL Plasmodium berghei ANKA acid phosphatase 40-48
H-2Kd 376 SYIPSAEKI Plasmodium berghei CSP 252-260
H-2Kd 2290 SYVPSAEQI Plasmodium CSP
H-2Kd 771 YYIPHQSSL Plasmodium falciparum Liver stage antigen 1671-1679


(back to top)

Minor Histocompatibility Antigen

Publications citing miHAg Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
A*01:01 652 IVDCLTEMY DRRFY (1521-1529))
A*02:01 581 RTLDKVLEV miHAg HA-8
A*02:01 175 FIDSYICQV miHAg H-Y (human SMCY) 311-319
A*02:01 473 VLHDDLLEA Minor Histocompatibility Antigen HA-1 137-145
A*02:01 395 YIGEVLVSV HA-2
B*07:02 1113 SPSVDKARAEL MiHAg SMCY 1041-1051
H-2Db 328 KCSRNRQYL miHAg SMCY 738-746
H-2Db 327 WMHHNMDLI miHAg UTY 246-254
H-2Kk 269 TENSGKDI SMCY 1332-1339


(back to top)

Model Antigen

Publications citing Model Antigen Pentamers

ALLELE PEPTIDE CODE PEPTIDE SEQUENCE EPITOPE ORIGIN
H-2Kb 093 SIINFEKL